Risk Factors for Thrombosis in Children with Cyanotic Congenital Heart Disease

Title: Risk Factors for Thrombosis in Children with Cyanotic Congenital Heart Disease

Authors: Alyaa Amal Kotby, Nevin Mohamed Mamdouh, Deena Samir Eissa, Neveen Talha Ahmed

DOI: https://dx.doi.org/10.18535/jmscr/v4i10.44

Abstract

References

Corresponding Author

Abstract

Mechanisms of hypercoagulability in cyanotic congenital heart disease (CCHD) are not fully elucidated, but endothelial dysfunction, hemostatic abnormalities, hyperviscosity, and iron deficiency are proposed underlying factors. We aimed to evaluate the risk factors for thrombosis in children with CCHD. Forty children with CCHD and 47 matched healthy controls were enrolled. Patients were divided into: Group I; 14 (35%) with history of thrombosis and Group II; 26 (65%) without history of thrombosis. Laboratory assays included complete blood count, serum iron profile and serum thrombomodulin level. CCHD patients had higher hemoglobin and hematocrit, lower mean corpuscular volume, mean corpuscular hemoglobin, platelets, iron and thrombomodulin than the control group. Group I showed higher hematocrit and lower platelets than Group II. No significant difference in iron profile and thrombomodulin was found between the patient groups. Thrombomodulin was positively correlated to oxygen saturation in all, Group I and Group II patients. CCHD is associated with a hypercoagulable state and a multifactorial risk for thrombosis. Decreased thrombomodulin is a reliable marker for endothelial dysfunction, however not a good marker for predicting thrombosis in children with CCHD. Infections and dehydration, increased hematocrit, and platelet activation are speculated to substantially participate in the prothrombotic state encountered in CCHD.

Keywords: cyanotic congenital heart disease; risk factors; thrombosis; thrombomodulin.

References

1. Kajimoto H, Nakazawa M, Murasaki K, Mori Y, Tanoue K, Kasanuki H, Nakanishi T. Increased thrombogenesity in patients with cyanotic congenital heart disease. Circ J 2007; 71: 948-953.

2. Cordina RL, Celermajer DS. Chronic cyanosis and vascular function: implica-tions for patients with cyanotic congenital heart disease. Cardiol Young 2010; 20: 242-253.

3. Dusse L, Godoi L, Kazmi RS, Alpoim P, Petterson J, Lwaleed BA, Carvalho M. Sources of thrombomodulin in pre-eclampsia: renal dysfunction or endothelial damage? Semin Thromb Hemost 2011; 37: 153-157.

4. Tay EL, Peset A, Papaphylactou M, Inuzuka R, Alonso-Gonzalez R, Giannak-oulas G, Tzifa A, Goletto S, Broberg C, Dimopoulos K, Gatzoulis MA. Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. Int J Cardiol 2011; 151: 307-312.

5. DeFilippis AP, Law K, Curtin S, Eckman JR. Blood is thicker than water: the management of hyperviscosity in adults with cyanotic heart disease. Cardiol Rev 2007; 15: 31-34.

6. Perloff JK. Neurologic disorders. In: Perloff JK, Child JS, eds. Congenital Heart Disease in Adults, 2nd ed. Philadelphia: WB Saunders; 1998: 237-246.

7. Silversides CK, Granton JT, Konen E, Hart MA, Webb GD, Therrien J. Pulmonary thrombosis in adults with Eisenmenger syndrome. J Am Coll Cardiol 2003; 42: 1982-1987.

8. Yamashita T, Sekiguchi A, Iwasaki YK, Sagara K, Hatano S, Iinuma H, Aizawa T, Fu LT. Thrombomodulin and tissue factor pathway inhibitor in endocardium of rapidly paced rat atria. Circulation 2003; 108: 2450-2452.

9. Kumada T, Dittman WA, Majerus PW. A role for thrombomodulin in the pathogen-nesis of thrombin-induced thromboembo-lism in mice. Blood 1988; 71: 728-733.

10. Gomi K, Zushi M, Honda G, Kawahara S, Matsuzaki O, Kanabayashi T, Yamamoto S, Maruyama I, Suzuki K. Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. Blood 1990; 75: 1396-1399.

11. Healy AM, Hancock WW, Christie PD, Rayburn HB, Rosenberg RD. Intravascular coagulation activation in a murine model of thrombomodulin deficiency: Effects of lesion size, age, and hypoxia on fibrin deposition. Blood 1998; 92: 4188-4197.

12. Rose SS, Shah AA, Hoover DR, Saidi P. Cyanotic congenital heart disease (CCHD) with symptomatic erythrocytosis. J Gen Intern Med 2007; 22: 1775-1777.

13. Lill MC, Perloff JK, Child JS. Pathogenesis of thrombocytopenia in cyanotic congenital heart disease. Am J Cardiol 2006; 98: 254-258.

14. Ismail EA, Youssef OI. Platelet-derived microparticles and platelet function profile in children with congenital heart disease. Clin Appl Thromb Hemost 2013; 19: 424-432.

15. West DW, Scheel JN, Stover R, Kan J, DeAngelis C. Iron deficiency in children with cyanotic congenital heart disease. J Pediatr 1990; 117(2 Pt 1): 266-268.

16. Olcay L, Ozer S, Gürgey A, Saraçlar M, Ozme S, Bilgiç A, Ozkutlu S, Celiker A. Parameters of iron deficiency in chil-dren with cyanotic congenital heart dise-ase. Pediatr Cardiol 1996; 17: 150-154.

17. Onur CB, Sipahi T, Tavil B, Karademir S, Yoney A. Diagnosing iron deficiency in cyanotic heart disease. Indian J Pediatr 2003; 70: 29-31.

18. Kaemmerer H, Fratz S, Braun SL, Koelling K, Eicken A, Brodherr-Heberlein S, Pietrzik K, Hess J. Erythrocyte indexes, iron metabolism, and hyperhomocys-teinemia in adults with cyanotic congenital cardiac disease. Am J Cardiol 2004; 94: 825-828.

19. Franchini M, Targher G, Montagnana M, Lippi G. Iron and thrombosis. Ann Hematol 2008; 87: 167-173.

Abstract

References

Corresponding Author

Call For Paper Volume 12 Issue 12 December 2024

JMSCR Menu

Impact Factor SJIF 2024: 7.892

Crossref - DOI

Editorial Policy

Frequency of Publication

Submission of Articles

Search